Retatrutide: The Triple‑Agonist
Triple Incretin–Glucagon Receptor Agonist for Metabolic Research (GLP-1 / GIP / Glucagon)
Retatrutide is a weekly, long-acting tri-agonist that activates GLP-1, GIP, and glucagon receptors—a next-generation tool for studying weight regulation, glycemia, energy expenditure, and hepatic fat metabolism. Our dual-chamber Snap Pen stores the peptide and bacteriostatic diluent separately; twist to snap the internal seal, gently invert to mix, then prime and dispense—preserving material integrity until first use.
How It Works (Mechanistic Context)
GLP-1R agonism → potentiates glucose-dependent insulin secretion, slows gastric emptying, reduces appetite/energy intake.
GIPR agonism → augments post-prandial insulin response and complements GLP-1 actions on glycemia.
Glucagon receptor (GCGR) agonism → increases energy expenditure and fatty-acid utilization; when balanced with GLP-1/GIP, supports weight-loss biology and hepatic lipid mobilization.
Suggested Research Applications (non-exhaustive)
Obesity & energy balance: appetite control, indirect calorimetry, substrate use, activity-independent EE.
Glycemic control: glucose-tolerance and clamp studies, β-cell function, incretin synergy.
Body-composition studies: DXA/MRI endpoints for fat mass and lean mass dynamics.
Hepatic steatosis / MAFLD models: liver-fat change and lipid flux with tri-agonism.
Key Features (for Research Use)
- Triple receptor agonism (GLP-1/GIP/GCGR) – for comprehensive incretin–glucagon axis modeling.
- Once-weekly profile – suitable for chronic metabolic study designs.
- Snap Pen format – on-demand reconstitution, clear graduations for repeatable aliquots, cold-chain fulfillment.
- QC & docs – high-purity material, endotoxin tested; COA + SDS provided per lot.
Research Sources
- Phase 2 obesity trial (48 weeks) — large, sustained weight reductions with weekly retatrutide.
- Type 2 diabetes (Phase 2) — robust A1c and weight effects; dose-ranging data.
- Body-composition sub study — fat-mass reduction vs. placebo/dulaglutide.
- Liver fat / MAFLD substudy — reduced liver fat in participants from the obesity trial.
- Mechanistic & class reviews (dual/triple agonists)
- Nature (GLP-1R mechanisms; tri-agonists context)
Technical Information
CAS Number: | 2381089-83-2 |
PubChem CID: | 171390338 |
Formula: | C221H342N46O68 |
Synonyms: | Retatrutide, 2381089-83-2, EX-A7826E, GTPL13769 |


